Effectiveness of Opicapone in Parkinson's according to baseline use of dopamine agonists: the real-world OPTIPARK study

被引：0
作者：
Jost, W. [1 ]
Reichmann, H. [2 ]
Lees, A. [3 ]
Marinho, D. [4 ]
Magalhaes, D. [4 ]
Rocha, J. F. [4 ]
Soares-da-Silva, P. [4 ]
机构：
[1] Parkinson Klin Ortenau, Wolfach, Germany
[2] Univ Dresden, Dept Neurol, Dresden, Germany
[3] Natl Hosp Neurol & Neurosurg, Dept Clin & Movement Neurosci, London, England
[4] BIAL Portela & Ca SA, Coronado, Portugal
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷
关键词：
MOTOR FLUCTUATIONS; LEVODOPA; DISEASE; ADJUNCT;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-747
引用
收藏
页码：905 / 905
页数：1
相关论文
共 50 条
  • [41] Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
    Costa, R.
    Lees, A.
    Ferreira, J.
    Rascol, O.
    Stocchi, F.
    Ikedo, F.
    Magalhaes, D.
    Rocha, J.
    Soares-Da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 457 - 457
  • [42] Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
    Ikedo, F.
    Lees, A.
    Ferreira, J.
    Rascol, O.
    Stocchi, F.
    Costa, R.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2019, 34 : S48 - S48
  • [43] Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data
    Costa, R.
    Lees, A.
    Ferreira, J.
    Rascol, O.
    Stocchi, F.
    Ikedo, F.
    Magalhaes, D.
    Rocha, F.
    Soares-da-Silva, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [44] Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis
    Binde, Caroline D.
    Tvete, Ingunn F.
    Gasemyr, Jorund, I
    Natvig, Bent
    Klemp, Marianne
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (12) : 1731 - 1743
  • [45] Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson's disease
    Powers, Rob
    Etezadi-Amoli, Maryam
    Arnold, Edith M.
    Kianian, Sara
    Mance, Irida
    Gibiansky, Maxsim
    Trietsch, Dan
    Alvarado, Alexander Singh
    Kretlow, James D.
    Herrington, Todd M.
    Brillman, Salima
    Huang, Nengchun
    Lin, Peter T.
    Pham, Hung A.
    Ullal, Adeeti, V
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (579)
  • [46] Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson's Disease
    Bacchin, Ruggero
    Liccari, Marco
    Catalan, Mauro
    Antonutti, Lucia
    Manganotti, Paolo
    Malaguti, Maria Chiara
    Giometto, Bruno
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 361 - 368
  • [47] Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
    Caraceni, T
    Musicco, M
    PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) : 107 - 114
  • [48] Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
    Daniel Ecker
    Alexander Unrath
    Jan Kassubek
    Michael Sabolek
    BMC Neurology, 9
  • [49] Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
    Ecker, Daniel
    Unrath, Alexander
    Kassubek, Jan
    Sabolek, Michael
    BMC NEUROLOGY, 2009, 9
  • [50] The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study
    Pellicano, Clelia
    Benincasa, Dario
    Fanciulli, Alessandra
    Latino, Pamela
    Giovannelli, Morena
    Pontieri, Francesco E.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2013, 18
12345